Clinical trial · Observational
Lymphatic Mapping After Previous Breast Surgery
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Rationale: Like in primary breast cancer, prognosis in recurrent breast cancer is correlated with regional lymph node status. Therefore, axillary staging may be warranted in patients with recurrent disease and intact axillary nodes, although this has not been described in guidelines yet. The lymphatic drainage pathways in the breast and/or axilla could have been changed due to prior surgery and/or radiotherapy. These aberrant drainage pathways could be detected with lymphatic mapping and sentinel node biopsy (SNB), leading to a more accurate staging. Objective: To assess the technical feasibility of lymphoscintigraphy after prior breast surgery. A second goal is to investigate whether or not previous breast surgery (with or without radiotherapy) significantly changes the lymphatic drainage pathways of the breast.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Sentinel Node | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lymphoscintigraphy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Sentinel Node Biopsy
- description
- All women who has Sentinel Node Biopsy as their primary treatment of the axilla
- interventionNames
- Radiation: Lymphoscintigraphy
- label
- Axillary Lymph Node Dissection
- description
- All women who had Axillary Lymph Node Dissection as primary axillary treatment
- interventionNames
- Radiation: Lymphoscintigraphy
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * treatment with BCT with SNB and/or ALND for primary breast cancer * previous primary breast cancer located in the upper-outer quadrant of one breast * Primary breast cancer treatment at least 3 years before the analysis, with or without adjuvant chemo- or hormonal therapy. Exclusion Criteria: * breast surgery for other reasons than breast cancer * recurrent breast cancer * former allergic reaction to 99mTc-colloidal albumin.
References
Publications (0)
Data not yet available